Multidisciplinary Team Strategies for Managing Tardive Dyskinesia
November 12, 2020
November 12, 2021
Scroll to the Bottom of this Information to Begin this Course
Supported by an educational grant from Teva Pharmaceuticals.
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
- Nurses — 0.75 American Nurses Credentialing Center (ANCC) credit
All other health care professionals completing this course will be issued a statement of participation.
This educational activity is designed for psychiatrists, PAs, NPs, APRNs, nurses, and other allied healthcare professionals interested in treatment and management of neurological disorders.
Dive into this engaging, digital newsletter created by our multidisciplinary faculty panel, Christoph Correll, MD and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC to learn proper recognition and management of tardive dyskinesia (TD). This newsletter includes guidance on diagnostic criteria, treatment algorithms, as well as strategies with how to incorporate novel therapies while ensuring optimal adherence and patient quality of life.
Upon completion of this activity, participants should be able to:
- Evaluate multidisciplinary strategies to identify possible patient population(s) that may be at increased risk for tardive dyskinesia
- Discuss the consequences of tardive dyskinesia that may decrease a patient's quality of life and adherence to treatment for concomitant disorders
- Recognize the risks and possible complications associated with managing tardive dyskinesia with off-label therapies
- Describe current differential diagnostic and evidence-based treatment algorithms for patients with tardive dyskinesia
- Interpret the clinical trial efficacy and safety data of novel and emerging therapies for tardive dyskinesia
Christoph U. Correll, MD (Chair)
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Professor of Psychiatry
The Zucker Hillside Hospital
New York, NY
Rose Mary Xavier, PhD, MS, RN, PMHNP-BC (Nurse Planner)
UNC Chapel Hill School of Nursing
Adult Psychiatric Mental Health Nurse Practitioner
Chapel Hill, NC
Physician Continuing Medical Education
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This nursing continuing professional development activity was approved by the American Association of Neuroscience Nurses, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
MIPS Improvement Activity
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Christoph U. Correll, MD
- Advisor, Consulting Agreements, and/or Honorarium Recipient: Acadia; Alkermes; Allergan; Angelini; Axsome; Gedeon Richter; Indivior; IntraCellular Therapies; Janssen/J&J; LB Pharma; Lundbeck; MedAvante-ProPhase; Merck & Company; Mylan; Neurocrine; Noyen; Otsuka; Pfizer, Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon; Sunovion; Supernus; Takeda; and Teva Pharmaceuticals
- Expert Testimony: Janssen; Otsuka
- Data Safety Monitoring Board: Lundbeck; Rovi; Supernus; and Teva Pharmaceuticals
- Grants/Research Support: Janssen; Takeda
- Stock Shareholder: LB Pharma
Rose Mary Xavier, PhD, MS, RN, PMHNP-BC has nothing to disclose.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Melissa Stradal at 773-714-0705 x160.
Hardware and Software Requirements
- Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
- Compatible with Windows PC and MAC (256 MB of RAM or higher)
- Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
- Adobe Flash Player 12.0 (or higher).
- Adobe Reader to print certificate.
- Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Biperiden, trihexyphenidyl, benztropine, procyclidine, amantadine, clonazepam, propranolol, tetrabenazine, levetiracetam, zonisamide, and nutritional supplements (eg, branch-chain amino acids, Yi-gin san, gingko biloba, melatonin, omega-3 fatty acids, resveratrol, vitamin B6, and vitamin E).
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.